Synertec Corporation Ltd’s (ASX:SOP) subsidiary has signed a $7.7 million contract to design and build a state of the art bacterial fermentation manufacturing facility in regional Victoria.
The client is one of the largest vaccine manufacturers in the world and the awarded project is part of a regional strategy to develop their facility as a global centre of excellence for Leptospirosis antigen production.
When complete, the expansion works will more than quadruple the facility’s current capacity.
Uniquely positioned to deliver the project
Synertec managing director Michael Carroll said: “We are delighted to be delivering a “state of the art” expansion to the animal vaccine facility.
“This complex and highly regulated project is one which Synertec is uniquely positioned to deliver.
“Furthermore, I am pleased that our contracted work in hand is growing strongly for FY19 on the back of this and other recent announcements.”
READ: Synertec Corporation enters 2018 with strong work book across its engineering business
In January, Synertec was awarded a $1.8 million contract to replace the control and monitoring system of the Melbourne Underground Rail Loop (MURL) fire and life system.
While releasing its half-year result, management highlighted that the company’s prospects for 2018 were enhanced by its strong work in hand.
Contracts awarded recently include two with North Caspian Operating Company N.V. Kazakhstan (NCOC).
This involved the design and supply of instrumentation, electrical and mechanical equipment for a project in the Kashagan field, one of the world’s largest offshore petroleum developments.